Zacks: Analysts Expect Becton, Dickinson and Company (BDX) to Post $2.43 EPS
Equities research analysts expect that Becton, Dickinson and Company (NYSE:BDX) will announce earnings per share of $2.43 for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Becton, Dickinson and’s earnings, with the highest EPS estimate coming in at $2.59 and the lowest estimate coming in at $2.26. Becton, Dickinson and reported earnings per share of $2.33 in the same quarter last year, which suggests a positive year over year growth rate of 4.3%. The business is scheduled to report its next quarterly earnings results on Thursday, February 1st.
According to Zacks, analysts expect that Becton, Dickinson and will report full-year earnings of $10.63 per share for the current fiscal year, with EPS estimates ranging from $10.57 to $10.81. For the next financial year, analysts anticipate that the business will post earnings of $11.80 per share, with EPS estimates ranging from $11.61 to $12.59. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Becton, Dickinson and.
Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.12 EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in BDX. Marshall & Sullivan Inc. WA lifted its stake in Becton, Dickinson and by 3.1% in the first quarter. Marshall & Sullivan Inc. WA now owns 20,707 shares of the medical instruments supplier’s stock valued at $3,826,000 after purchasing an additional 618 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and in the first quarter valued at approximately $105,000. Puzo Michael J purchased a new position in Becton, Dickinson and in the first quarter valued at approximately $202,000. OLD Mutual Customised Solutions Proprietary Ltd. lifted its stake in Becton, Dickinson and by 13.4% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 7,102 shares of the medical instruments supplier’s stock valued at $1,303,000 after purchasing an additional 838 shares during the last quarter. Finally, Colony Group LLC lifted its stake in Becton, Dickinson and by 13.0% in the first quarter. Colony Group LLC now owns 11,650 shares of the medical instruments supplier’s stock valued at $2,137,000 after purchasing an additional 1,342 shares during the last quarter. Hedge funds and other institutional investors own 88.46% of the company’s stock.
Shares of Becton, Dickinson and (NYSE:BDX) opened at $219.68 on Monday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The company has a market capitalization of $50,082.20, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 1.72 and a beta of 1.07. Becton, Dickinson and has a twelve month low of $161.50 and a twelve month high of $229.68.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, December 7th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s payout ratio is presently 64.52%.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Becton, Dickinson and Company (BDX) to Post $2.43 EPS” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/zacks-analysts-expect-becton-dickinson-and-company-bdx-to-post-2-43-eps.html.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.